.jpg)
A CHAMIGRENIC COMPOUND AS A NAEGLERIA FOWLERI INFECTION TREATMENT.
Patent number:
P202230496
No items found.
The invention discloses the use of a sesquiterpene compound for the treatment or prevention of primary amebic meningoencephalitis (PAM) caused by Naegleria fowleri in a human or animal subject, preferably of the compound (+)- elatol, and the pharmaceutical composition containing said compound.
Countries:
Spain
Regions:
Canary Islands
Centers:
UNIVERSIDAD DE LA LAGUNA
Other entities:
Universidad Federal de Río de Janeiro
Sectors:
Chemicals
Subsectors:
TRL Level:
TRL 3 – experimental proof of concept
BRL Level:
PDF Link:
Download hereVideo Link:
Watch it hereSustainable Development Goal:
SDG03: Good health and well-being
Applications
High selectivity index Low toxicity values Alternative to existing treatments Treatment of diseases caused by "brain-eating amoeba"
Comments
Other related patents
Health
Chemicals
Food & Agro
BINARY COMPLEX OF AN ORGANIC ZINC CHELATE AND FLAVONOIDS AND COMPOSITION COMPRISING IT FOR STIMULATING THE IMMUNE SYSTEM AND ENHANCING RESISTANCE TO VIRAL OR BACTERIAL INFECTIOUS DISEASES
Chemicals
AUTONOMOUS WATER TREATMENT SYSTEM
Health
Chemicals
Other
Energy